Breast Cancer Trial, Recruiting NCT07446868 Sponsor: Cairo University Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT07446868
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women who have been diagnosed with breast cancer
  • People who are scheduled to have a type of surgery called a modified radical mastectomy (a procedure to remove the breast and some nearby lymph nodes)
  • People whose overall health before surgery falls within a moderate risk range, as classified by anaesthesia guidelines (known as ASA physical status II or III — confirm with trial site if unsure which category applies)
  • People aged between 18 and 65 years
  • People whose body weight relative to their height (BMI) is greater than 20 and less than 35
  • People who are able to understand the study procedures and sign a written consent form

Who may not be able to join:

  • People who do not wish to take part
  • People whose overall health is classified as very high risk under anaesthesia guidelines (ASA physical status IV or higher)
  • People whose BMI is 20 or below, or 35 or above
  • People who have a known allergy or medical reason to avoid local anaesthetics, opioids, or other medications used in the study
  • People who have a history of long-term (chronic) pain or who regularly use opioid pain medications
  • People who have significant mental health conditions that may affect how pain is measured or reported
  • People for whom regional anaesthesia (numbing a specific area of the body by injection) is not medically suitable — for example, due to an infection near the injection site, a blood clotting problem, or existing nerve damage
  • People who have severe disease affecting the lungs, heart, liver, or kidneys

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sayed M Abed, MD, Associate Professor of Anesthesia and Pain Management, National Cancer Institute -- Cairo University

Phone: +20 122 680 6532

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 March 2026
Est. completion
1 March 2027

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Total 24-Hour Postoperative Morphine Consumption

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov